-
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2
Chen, S., Wang, Q., Christodoulou, A., Mylonas, N., Bakker, D., Nederlof, R., Hollmann, M. W., Weber, N. C., Coronel, R., Wakker, V., Christoffels, V. M., Andreadou, I. & Zuurbier, C. J., 17 Jan 2023, In: Circulation. 147, 3, p. 276-279 4 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
Chen, S., Schumacher, C. A., van Amersfoorth, S. C. M., Fiolet, J. W. T., Baartscheer, A., Veldkamp, M. W., Coronel, R. & Zuurbier, C. J., 2023, In: Frontiers in physiology. 14, 1179131.Research output: Contribution to journal › Article › Academic › peer-review
-
Direct cardiac effects of SGLT2 inhibitors
Chen, S., Coronel, R., Hollmann, M. W., Weber, N. C. & Zuurbier, C. J., 1 Dec 2022, In: Cardiovascular diabetology. 21, 1, 45.Research output: Contribution to journal › Review article › Academic › peer-review
- All publications